Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.44
13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Oncoclinicas do Brasil Servicos Medicos SA
Wall Street
Price Targets
ONCO3 Price Targets Summary
Oncoclinicas do Brasil Servicos Medicos SA
According to Wall Street analysts, the average 1-year price target for
ONCO3
is 9.49 BRL
with a low forecast of 7.07 BRL and a high forecast of 13.65 BRL.
Revenue
Forecast
Revenue Estimate
Oncoclinicas do Brasil Servicos Medicos SA
For the last 4 years the
compound annual growth rate for
Oncoclinicas do Brasil Servicos Medicos SA's revenue is
34%.
The projected
CAGR
for the next 3 years is
16%.
Operating Income
Forecast
Operating Income Estimate
Oncoclinicas do Brasil Servicos Medicos SA
For the last 4 years the
compound annual growth rate for
Oncoclinicas do Brasil Servicos Medicos SA's operating income is
59%.
The projected
CAGR
for the next 3 years is
19%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ONCO3's stock price target?
Price Target
9.49
BRL
According to Wall Street analysts, the average 1-year price target for
ONCO3
is 9.49 BRL
with a low forecast of 7.07 BRL and a high forecast of 13.65 BRL.
What is Oncoclinicas do Brasil Servicos Medicos SA's Revenue forecast?
Projected CAGR
16%
For the last 4 years the
compound annual growth rate for
Oncoclinicas do Brasil Servicos Medicos SA's revenue is
34%.
The projected
CAGR
for the next 3 years is
16%.
What is Oncoclinicas do Brasil Servicos Medicos SA's Operating Income forecast?
Projected CAGR
19%
For the last 4 years the
compound annual growth rate for
Oncoclinicas do Brasil Servicos Medicos SA's operating income is
59%.
The projected
CAGR
for the next 3 years is
19%.
What is Oncoclinicas do Brasil Servicos Medicos SA's Net Income forecast?
Projected CAGR
27%
The
compound annual growth rate
of Oncoclinicas do Brasil Servicos Medicos SA's net income for the next 3 years is
27%.
You don't have any saved screeners yet
